FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery

Thumbnail
2015
2465.pdf (294.4Kb)
Authors
Petrović, Stanislava
Bogavac-Stanojević, Nataša
Lakić, Dragana
Peco-Antić, Amira
Vulicević, Irena
Ivanišević, Ivana
Kotur-Stevuljević, Jelena
Jelić-Ivanović, Zorana
Article (Published version)
Metadata
Show full item record
Abstract
Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility m...easurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.

Keywords:
acute kidney injury / cardiac surgery / children / biomarkers / cost effectiveness analysis
Source:
Biochemia Medica, 2015, 25, 2, 262-271
Publisher:
  • Croatian Soc Medical Biochemists, Zagreb
Funding / projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

DOI: 10.11613/BM.2015.027

ISSN: 1330-0962

PubMed: 26110039

WoS: 000356588100014

Scopus: 2-s2.0-84930421453
[ Google Scholar ]
16
13
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2467
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Petrović, Stanislava
AU  - Bogavac-Stanojević, Nataša
AU  - Lakić, Dragana
AU  - Peco-Antić, Amira
AU  - Vulicević, Irena
AU  - Ivanišević, Ivana
AU  - Kotur-Stevuljević, Jelena
AU  - Jelić-Ivanović, Zorana
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2467
AB  - Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.
PB  - Croatian Soc Medical Biochemists, Zagreb
T2  - Biochemia Medica
T1  - Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery
VL  - 25
IS  - 2
SP  - 262
EP  - 271
DO  - 10.11613/BM.2015.027
ER  - 
@article{
author = "Petrović, Stanislava and Bogavac-Stanojević, Nataša and Lakić, Dragana and Peco-Antić, Amira and Vulicević, Irena and Ivanišević, Ivana and Kotur-Stevuljević, Jelena and Jelić-Ivanović, Zorana",
year = "2015",
abstract = "Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level). Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER). Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY. Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.",
publisher = "Croatian Soc Medical Biochemists, Zagreb",
journal = "Biochemia Medica",
title = "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery",
volume = "25",
number = "2",
pages = "262-271",
doi = "10.11613/BM.2015.027"
}
Petrović, S., Bogavac-Stanojević, N., Lakić, D., Peco-Antić, A., Vulicević, I., Ivanišević, I., Kotur-Stevuljević, J.,& Jelić-Ivanović, Z.. (2015). Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica
Croatian Soc Medical Biochemists, Zagreb., 25(2), 262-271.
https://doi.org/10.11613/BM.2015.027
Petrović S, Bogavac-Stanojević N, Lakić D, Peco-Antić A, Vulicević I, Ivanišević I, Kotur-Stevuljević J, Jelić-Ivanović Z. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. in Biochemia Medica. 2015;25(2):262-271.
doi:10.11613/BM.2015.027 .
Petrović, Stanislava, Bogavac-Stanojević, Nataša, Lakić, Dragana, Peco-Antić, Amira, Vulicević, Irena, Ivanišević, Ivana, Kotur-Stevuljević, Jelena, Jelić-Ivanović, Zorana, "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery" in Biochemia Medica, 25, no. 2 (2015):262-271,
https://doi.org/10.11613/BM.2015.027 . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB